Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.28 and traded as low as $0.23. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 3,969,233 shares trading hands.
Northwest Biotherapeutics Trading Up 7.2 %
The firm’s 50-day moving average is $0.26 and its 200-day moving average is $0.28. The firm has a market cap of $347.65 million, a price-to-earnings ratio of -3.15 and a beta of -0.52.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Read More
- Five stocks we like better than Northwest Biotherapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- What Investors Need to Know to Beat the Market
- 3 ETFs to Ride the VIX Surge During Market Volatility
- How to Short a Stock in 5 Easy Steps
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
